Harvard Bioscience (HBIO) risk factors
Item 1A of every Harvard Bioscience Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors24 risks3 new3 dropped2 reworded
The company faces heavy debt constraints under a 40.0 million dollar credit agreement and is restructuring manufacturing via Project Viking. Prior going concern doubts were dropped following debt adjustments and remediation of material control weaknesses.
Filed Mar 13, 2026 - FY2024 10-K risk factors24 risks
The company faces substantial going concern doubt due to a $37.4 million debt default under its Credit Agreement. Heavy reliance on pharmaceutical, biotechnology, and academic research budgets exposes earnings to funding cuts. Operations are heavily exposed to international markets, foreign currency fluctuations, and trade policy risks.
Filed Mar 14, 2025